BioSpace News Archive

The Lung Cancer Registry has launched a landmark new survey on the impact of lung treatments on women’s sexual health.

Agreement centers on identifying HER2 gene mutations using Oncomine Dx Target Test

Hard surface disinfectant formulations with Glyclean™AM as the active ingredient effectively kill SARS-CoV-2, the virus that causes COVID-19.

Salesforce and Siemens announced a strategic partnership to develop a new workplace technology suite that will support businesses globally to safely reopen and deliver the future experience for physical workplaces.

Schrödinger announced a strategic collaboration with Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery.

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced a significant expansion of its work to discover novel antiviral therapeutics for COVID-19 as a part of a philanthropic global initiative.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The decision was made after assessing the totality of the data including the 500 mg cohort, the highest dose studied in the trial. “Alth

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, addresses the challenges of developing new precision oncology medicines by unveiling the GuardantINFORM ™ platform featuring an extensive clinical-genomic liquid biopsy dataset of advanced cancer patients. The GuardantINFORM platform is intended to help accelerate research and development of the next generation of cancer therapeutics by offering biopharma partne

-Pete Curry has been Promoted to Vice President of Sales - Maria Pandolfo has been Promoted to Vice President of Patient Services

Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will be featured in a webinar, “Grand Rounds: A Webinar in Biotech and Specialty Pharma,” hosted by James Molloy, Managing Director of Equity Research, Biotechnology and Specialty Pharmaceuticals at Alliance Gl